The in vitro effects of aprotinin on twelve different ACT tests.

Aprotinin is frequently used during CPB to reduce post-operative bleeding and attenuate the inflammatory response. The level of anticoagulation in these patients is monitored by using various activated clotting time (ACT) tests, which are generally accepted as being altered by the presence of aprotinin in blood. Therefore, we have investigated the effect of aprotinin on several ACT tests using whole blood from CPB patients. With IRB approval, blood samples were collected from patients undergoing CPB before and after full heparinization (300 u/kg). Each blood sample was divided into two aliquots, and aprotinin was added to one of them to yield a final calculated concentration of 300 KIU/mL. Both aliquots were used simultaneously to perform the 12 ACT tests. A paired Student's t-test was performed on the data. Overall, test results from 9 of 12 devices were significantly increased by aprotinin. Of these, four were increased only when the sample was heparinized, three were elevated by both heparinized and unheparinized blood, and two were elevated only when the sample was unheparinized. Each affected test responded uniquely to aprotinin, producing ACT test results ranging from 12 to 51% above nonaprotinized values. Several tests that were affected by aprotinin using heparinized blood samples were unaffected using unheparinized blood samples. These data emphasizes the unique manner in which individual ACT tests respond to aprotinized blood samples and should be considered when developing institutional policy for anticoagulation of aprotinized patients.